Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500114983) titled 'This study aims to evaluate the efficacy and safety of Disitamab Vedotin combined with Cisplatin and Candelinib in the treatment of patients with locally advanced cervical cancer' on Dec. 19, 2025.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Dalian Medical University Second Affiliated Hospital
Condition:
Cervical cancer
Intervention:
Trial group (Simon two-stage design, Phase 1):1. Neoadjuvant period:
Disitamab Vedotin (2.5 mg/kg, D1, iv, Q3W
three cycles in total)
Cisplatin (50 mg/m^2, D1, iv, Q3W
three cycles in total)
Cadonilimab (10 mg/kg, D1, iv, Q3W
three cycles i...